Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 FDA Approves Sanofi’s New Lice Treatment - Happi
Company News

FDA Approves Sanofi’s New Lice Treatment

Sklice lotion treats infestation in one application.

The US FDA has approved Sanofi’s Sklice (ivermectin) lotion, 0.5% for the topical treatment of head lice, in patients 6 months of age and older. Sklice Lotion, according to Sanofi, treats lice in most patients with a single 10-minute application of the lotion, without nit combing.


“The approval of Sklice Lotion provides physicians and parents with a new treatment option for head lice, a condition that is notoriously frustrating to treat,” said Kenneth P. Guito, general manager, Sanofi-Topaz. “Through a unique mode of action, Sklice Lotion resolves most head lice infestations in one application, and is very well-tolerated.”


Each year in the US, head lice infest an estimated 6 to 12 million children aged 3 to 11 years. Estimates for direct and indirect costs, which include millions of lost school days and lost work for parents, are as high as $1 billion.


Formulated with ivermectin, an antiparasitic that has been used orally for more than 20 years and more than 1 billion times to treat other parasites, Sklice Lotion was developed to meet the demand for an effective, convenient head lice treatment that works differently and is well-tolerated in children, according to Sanofi.


Sklice Lotion was developed by Topaz Pharmaceuticals, which was acquired by Sanofi Pasteur in October 2011.

Add us as a preferred source on Google

Get the latest Happi news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Happi Newsletters